Copyright @ BlueCatBio. All rights reserved.
Read our interview with High Content Review featuring the BlueWasher for high content cellular assays
More Productive Discovery
FLIPR ® is a registered trademark of Molecular Devices, LLC
Miss fewer active compounds
Reduce false positives
Fast, compact and quiet
Download presentation "Addressing the challenges of 1536-well cell based screening"given by AstraZeneca at SLAS2016
Simpler Assay Design
Centrifugation mimicks "dump and tap" - simple automation of manual SOPs
Our BlueWasher's award-winning ability to improve z' for adherent cellular assays makes it the most cost-effective tool to boost drug discovery productivity. With residual volumes 10x lower than conventional, tip-based plate washers, BlueWasher reduces assay background and variability, allowing imagers to produce even better data. Ideal for assay development, high-throughput screening (HTS), high-content screening (HCS), FLIPR®, or expression assays, including 1536w, as part of a fully automated system, or a stand-alone workstation.
BlueWasher may only be operated without wast pump in the area covered by the European Patent Office
Link to paper (see abstract below): "Enabling 1536-Well High-Throughput Cell-Based Screening through the Application of Novel Centrifugal Plate Washing." by Sinead Knight et. al., AstraZeneca
More Reliable Screens
No clogged needles,
more reproducible data
High Throughput, Small Footprint
Enabling 1536-Well High-Throughput Cell-Based Screening through the Application of Novel Centrifugal Plate Washing.
Knight S, Plant H, McWilliams L, Murray D, Dixon-Steele R, Varghese A, Harper P, Ramne A, McArdle P, Engberg S, Bennett N, Blackett C, Wigglesworth M.
Cell-based assays have long been important within hit discovery paradigms; however, improving the disease relevance of the assay system can positively affect the translation of small-molecule drug discovery, especially if adopted in the initial hit identification assay. Consequently, there is an increasing need for disease-relevant assay systems capable of running at large scale, including the use of induced pluripotent stem cells and donor-derived primary cells. Major hurdles to adopting these assays for high-throughput screening are the cost, availability of cells, and complex protocols. Miniaturization of such assays to 1536-well format is an approach that can reduce costs and increase throughput. Adaptation of these complex cell assays to 1536-well format brings major challenges in liquid handling for high-content assays requiring washing steps and coating of plates. In addition, problematic edge effects and reduced assay quality are frequently encountered. In this study, we describe the novel application of a centrifugal plate washer to facilitate miniaturization of a range of 1536-well cell assays and techniques to reduce edge effects, all of which improved throughput and data quality. Cell assays currently limited in throughput because of cost and complex protocols may be enabled by the techniques presented in this study.
1536-well; cell assays; high-throughput; miniaturization; phenotypic screening